Val av peptid CRO: En due-diligence-spelbok

Varför Peptid CRO-valet misslyckas när priset leder jämförelsen

Valet av peptid CRO börjar vanligtvis med en offertjämförelse, och det är där det blir fel. Enhetspris per milligram är den minst prediktiva variabeln i beslutet, eftersom den bara fångar synteskörningen, inte kostnaden för en partner vars metoder, dokumentation eller uppskalning håller inte.

Fellägena är dyra. En misslyckad överföring av läkemedelsteknik kostar mer än 5 miljoner USD före batchkostnader, med varje ingenjörs- och valideringsbatch som kör omkring 2,5 miljoner USD och överföringar sträcker sig vanligtvis 18 till 30 månader, enligt val genesis, med hänvisning till lagar (2026-04-12). Behandla det som en leverantörskonsultuppskattning, inte ett granskat riktmärke. deepceutix, citerar CDMO Live 2025 (2025-12-15) rapporterar att ungefär hälften av tekniköverföringarna drabbar kvalitetsproblem, och att externa överföringar lägger till 5.8 månader kontra interna; baspopulationen bakom dessa siffror avslöjas inte.

Key Takeaway: Ett lågt enhetspris förskjuter kostnaden till överföring, omarbetning och fördröjning, där siffrorna är en storleksordning större. De nio dimensionerna nedan är beställda för att stresstesta den billigaste offerten mot dessa fellägen.

Använd detta som en anpassad peptid CRO-checklista, inte en prislista.

Vad du ska fråga om synteskapacitet och rutt

Den checklistan börjar med en fråga som är skarpare än "kan du göra min sekvens": vilken väg du ska använda, och vad som händer med den vägen på tio gånger skalan? Peptidsyntes i fast fas (SPSS) hanterar de flesta sekvenser upp till ungefär 50 rester, men kedjelängden ensam avgör inte svaret. Hydrofobicitet, aggregationsbenägna sträckor och antalet icke-naturliga modifieringar driver en sekvens mot modifierad SPPS eller fragmentkondensering, och var och en av dessa vägar bär sin egen avskyddnings- och kopplingsstrategi.

Be om ett representativt batchregister för en sekvens av jämförbar längd och hydrofobicitet, plus föroreningsprofilen som följde med. Det enda dokumentet berättar mer än något kapacitetsuttalande, eftersom den visar rutten, hartset, kopplingsreagensen och reningsbasen tillsammans.

Publicerade skalanspråk är inte jämförbara utan dessa detaljer. Thermo Fisher citerar anpassad peptidsyntes från 0.1 mg till 1 kg eller mer, Bachem listar icke-GMP-peptidproduktion från 5 mg till 100 g kl 80 till 97 procent renhet, och AAPPTec annonserar GMP-syntes från hundratals milligram till multi-kilogram kvantiteter. Inget av dessa intervall betyder något förrän leverantören anger rutten och renhetsgrunden bakom dem.

Felläget som detta förhindrar är specifikt: en sträcka som fungerar rent kl 50 mg och kan inte skalas, upptäcks först efter att ditt program har förbundit sig till partnern och tidslinjen.

Hur man testar skalflexibilitet innan du förbinder dig

Peptiduppskalningsflexibilitet är inte det intervall som skrivs ut på en leverantörs kapacitetssida. Det är en dokumenterad förändringskontrollberättelse som visar vad som händer med rutten, kontrollerna under processen och frisättningstesten när partiet växer.

Geografi är ett användbart första filter, och även ett bra ställe att fånga en overreach. Asien-Stillahavsområdet har 45–50 % av den globala tillverkningskapaciteten för peptid-API i volym, with China alone at 30–35%, enligt peptidestaff’s 2026 market review. The same source cautions that revenue and regulated-capacity distribution is more balanced, so a regional volume claim and a regulated-capacity claim are two different claims. Ask which one the vendor is actually making.

Then ask three questions: at which scale does the route change, which in-process controls are added at each step, and which release tests are added. Demand a scale-up report or comparability protocol covering milligram to gram to multi-gram. Utan det, a program can pass at lab scale and fail at the first GMP campaign.

Vad ändrings- och märkningsexpertis faktiskt kräver

Peptide modification services and peptide labeling and tagging are not one capability, and treating them as one is how buyers end up paying for chemistry a partner has never characterized. Noncanonical amino acid incorporation, disulfide formation and cyclization, lipidering, PEGylering, and dye, fluorophore or affinity-tag conjugation each carry separate synthesis routes, separate purification behavior and separate analytical confirmation problems. The question is not whether a vendor offers the class. It is whether the vendor has made that specific class before.

Peptidsyntes Ask for a prior batch record or certificate of analysis for a sequence carrying the same modification, and for the analytical method used to confirm where the modification sits. A mass shift alone tells you the conjugate formed; it does not tell you it formed at the intended residue. Without positional confirmation, isomer mixtures surface at release testing, when rework costs the most.

Tjänster Labeling chemistry often carries its own IP exposure, which the confidentiality questions later in this playbook pick up.

Hur djupt bör analytisk karakterisering gå

Peptide analytical characterization is not a question of whether a partner runs HPLC and MS, but of what the release panel detects that a purity-by-area-% figure hides. GenScript’s quality documentation notes that the area % of the target peptide is used to calculate HPLC purity (GenScript quality page, hämtas 2026-08-03). That makes a headline “>98%” a method-dependent claim, not a universal one, because the number depends on the column, lutning, and detection wavelength chosen.

A defensible release panel states its conditions rather than reporting a bare figure:

Validation expectations should be anchored to ICH Q2(R2), which sets out how analytical procedures are validated for their intended purpose. Ask for the actual chromatogram and mass spectrum from a representative batch, not a summary table. A purity number that cannot be reproduced under the receiving lab’s conditions is the failure mode this dimension exists to prevent.

Dokumentation, CoA och dataintegritet: Vad man ska kräva

Peptide documentation and CoA review is where most buyers stop too early. A certificate of analysis is only as useful as the data-integrity system behind it, and that system is what regulators examine when a filing is challenged.

The scale of the problem is visible in enforcement data. A 2026 analysis by peptidestaff counted data-integrity findings in FDA warning letters in roughly 30% of letters issued to Chinese API facilities since 2024; the reviewer’s count is stated without a disclosed sample frame, so treat it as a directional signal rather than a rate. The longer trend is firmer: val genesis, citing FDA data for 2022, reports more than 160 FDA data-integrity warning letters between 2017 och 2022, inklusive 13 i 2022 ensam.

Ask three questions of any peptide synthesis partner evaluation: Is the CoA batch-specific? Who signs it? Can audit trails be produced on request? Then hold the answers against MHRA’s ALCOA principles and a current ISO 13485 eller ISO 9001 certificate.

Key Takeaway: Demand a redacted, batch-specific CoA plus the audit-trail policy. A CoA that cannot be defended in a regulatory filing is a liability, inte dokumentation.

IP-hantering och konfidentialitetsfrågor som de flesta köpare hoppar över

Peptide IP and confidentiality exposure is wider than the sequence itself. It also covers the synthetic route, the analytical methods used to release your material, and the labeling or conjugation chemistry built on top of it. Ask four things before signing.

Who owns a route improvement discovered during the campaign? A vendor chemist who finds a better coupling or purification step may create intellectual property inside your project. The MSA should state whether that improvement belongs to you, to the vendor, or is jointly held, and under what licensing terms you can use it elsewhere.

What happens to that improvement if the relationship ends? Ownership without transfer rights is not useful. Confirm you can take the improved route, with its written procedure, to another peptide synthesis partner.

Does the proposed proprietary route carry freedom-to-operate risk? If a vendor offers a patented or proprietary route, ask who holds the patent and whether your use is covered.

How is labeling chemistry protected? Conjugation and labeling work often reveals more about your program than the peptide sequence does. Request the actual MSA and IP clauses, not a summary.

Omloppstider: Vad tidslinjepåståendet verkligen mäter

A quoted lead time is not one number. It is four clocks running at different speeds, and vendors rarely say which one they are quoting. Synthesis lead time covers the route, the resin loading and the purification runs. Analytical release time covers method qualification, the assay panel and any repeat testing a failing specification forces. Documentation turnaround covers the CoA, the data package and the QA sign-off that makes the material releasable. Queue position decides when your project starts at all, and it is the clock most often left unstated.

Market size tells you nothing about interchangeability. A 2026 survey of verified peptide manufacturers mapped 241 companies across 26 or more countries, med 119 FDA Drug Master File filings and 65 confirmed shipping to the United States. Capacity that broad still varies by route, scale and queue depth, so a shorter quote often reflects a quieter queue rather than a faster process.

Supply risk can stretch any of the four clocks after the quote is signed. Pharmaceutical-grade amino acid supply is concentrated, med över 80% originating from fewer than five countries. Ask each vendor which clocks their number covers, and what happens to it when a reagent shipment slips.

Tekniköverföring som en gated process, Inte ett steg

Peptide technology transfer is a sequence of gates, not a single handoff, and each gate needs acceptance criteria agreed before the work starts. The gates run in order: method transfer with predefined acceptance criteria, a comparability protocol, engineering batches, validation batches, and a documented method-transfer record. The cost and duration figures cited earlier describe the whole sequence, which is why treating any one gate as the finish line misreads the commitment.

The question to ask is narrow: what are the acceptance criteria for the method transfer, and who signs off that they were met? The evidence to demand is a completed method-transfer record from a prior program, not a summary of one. That record shows whether the receiving lab reproduced the assay under its own hands, which is the only proof that matters.

För tips: Write the acceptance criteria before the transfer begins. Criteria negotiated after the first data set arrives tend to bend toward whatever the lab produced.

Felläget som detta förhindrar är specifikt: a transfer declared complete before the receiving lab can reproduce the assay. Once that declaration is signed, the discrepancy surfaces later as a batch failure with no clean owner.

Poäng de nio dimensionerna: En jämförelsematris

The nine dimensions only become a decision tool once you weight them, and the first thing a custom peptide CRO checklist has to normalize is scope. Published market figures disagree because they measure different things: a wider-definition peptide CDMO figure puts the market at USD 4.59B in 2025 rising to USD 5.52B in 2026 vid a 20.3% CAGR (Läkemedelstillverkning, 2026-08-19), while a combined peptide and oligonucleotide CDMO figure gives USD 2.68B in 2025 and USD 2.98B in 2026 på 11.05% (Mordor Intelligence, 2026-07-31). Vendor claims inherit the same problem. Score each dimension 1 till 5, then apply stage weights: discovery favors route flexibility and speed, clinical favors analytical characterization and documentation, commercial favors scale and technology transfer. Treat data integrity, IP terms and transferability as disqualifying rather than low-scoring.

Ett fungerande exempel på ett komplett bevispaket

The fastest way to calibrate your scoring is to request one representative package and read it end to end. Ask for a completed program, not a template: a synthesis route with the impurity rationale behind it, frisläppnings- och stabilitetsdata för samma parti, a method transfer report with acceptance criteria and the actual results, and a CoA whose raw data are retrievable.

One example of what to ask for is the analytical and transfer documentation MOL Changes can be used to request as a representative package. Treat it as a benchmark rather than a recommendation, and score it against the same nine dimensions you apply elsewhere.

Then check replicability. If the package answers your questions but cannot be re-run by a second lab from the written record alone, det dokumenterar ett resultat snarare än en process. A complete submission lets your own team reproduce the result, which is the standard peptide CRO selection should be held to.

Vanliga misstag vid utvärdering av peptidpartner

Comparing vendors on price per milligram without a purity basis. A quote of $X per milligram means little until you know whether it is priced on crude, purified, or net-peptide basis, and at what scale and route. The fix is to normalize every quote to the same purity specification, the same scale, and the same synthesis route before you compare. Otherwise the cheapest number is often the one with the least material behind it.

Accepting a capability claim without a batch record. Anyone can say they run difficult sequences. Ask for a redacted batch record from a comparable program: the actual yields, the purification steps, the analytical results. If they cannot show one, treat the claim as unverified.

Treating peptide technology transfer as a formality. Transfer is a gated process with acceptance criteria, not a handover email. Build the gates into the timeline and the contract.

Accepting a summary CoA instead of a batch-specific one. A generic certificate tells you what the vendor can do, not what you received. Demand the batch-specific document.

Assuming a quoted lead time covers documentation and release. The synthesis date is not the release date. Ask what the quote includes and what it excludes.

Vanliga frågor

Kan jag utvärdera en peptid CRO utan en revision på plats?

Yes for early screening, no for a GMP commitment. A batch-specific certificate of analysis, a completed method-transfer record, the audit-trail policy for the chromatography data system, and current quality-system certification (ISO 13485 eller motsvarande) let you judge most of what a site visit would show. What they cannot replace is direct observation of material flow, segregation of quarantined batches, and how operators actually handle deviations. Treat peptide CRO selection as a two-stage decision: documents for the shortlist, an audit before you sign a GMP supply agreement.

Vad ska jag göra om metodöverföringen inte uppfyller acceptanskriterierna?

Stop the transfer and document the deviation before anything else. Then agree with the partner on a root-cause investigation covering the method, utrustningen, and the analyst, and re-run against the same predefined acceptance criteria. Do not renegotiate the criteria to make the second attempt pass. If the failure traces to the receiving laboratory rather than the method, that is a finding about the partner’s capability, not a reason to loosen the specification.

Hur förändras detta ramverk i kommersiell skala?

Dimensions that were merely preferred earlier become disqualifying. Scale flexibility and documentation completeness carry the most weight, because peptide technology transfer to commercial supply leaves little room for a partner who cannot demonstrate the route at the volumes you will need or produce records that survive regulatory inspection. Analytical depth also shifts from a differentiator to a baseline expectation.

Är en längre ledtid det bästa valet?

Ja, when the shorter quote excludes documentation, släpptestning, or queue risk. Compare timelines like for like: ask what is included in the stated window, whether release testing runs inside or after it, and how the partner handles a queue that slips. A quote that looks three weeks faster often ends up slower once those items are added back.

Slutsats och nästa steg

You now have a nine-dimension framework for peptide CRO selection: synthesis capability and route, scale flexibility, modification and labeling expertise, analytiskt djup, documentation and CoA practice, IP handling, turnaround reality, and technology transfer as a gated process. Two of those dimensions, peptide documentation and CoA integrity and peptide technology transfer, are disqualifying rather than merely low-scoring. A partner that fails them cannot be rescued by a lower quote.

That is the reframe worth keeping. Price per milligram is an output of the criteria you apply, not the criteria themselves. The dimensions that decide whether a program survives a filing are also the ones that are hardest to compare across vendors, which is why the scoring matrix matters more than the quote sheet.

Score your shortlist against the same nine dimensions Request a representative analytical and transfer package and score it against the checklist in this guide, exactly as you would score any other vendor. Request a representative analytical package

Avslöjande: MOL Changes publishes as a peptide vendor with a commercial interest in peptide quality standards.